|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Investment property, net | ||||||||||||||||||||
| Investments in real estate-related securities | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Derivative instruments | ||||||||||||||||||||
| Tenant and other receivables, net | ||||||||||||||||||||
| Intangible lease assets, net | ||||||||||||||||||||
| Right-of-use asset, net | ||||||||||||||||||||
| Financing lease right-of-use asset, net | ||||||||||||||||||||
| Deferred leasing costs, net | ||||||||||||||||||||
| Deferred financing costs, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Intangible lease liabilities, net | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Financing lease liability | ||||||||||||||||||||
| Financing obligations | ||||||||||||||||||||
| Derivative instruments | ||||||||||||||||||||
| Distributions payable | ||||||||||||||||||||
| Notes payable, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Commitments and contingencies (Note 13) | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred shares, $0.001 par value per share; 500,000 preferred shares authorized, none issued or outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common shares, $0.001 par value per share (Note 8) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated distributions in excess of earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
